Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders

Business Wire

Published

NEW YORK & GENEVA--(BUSINESS WIRE)--Neurosterix launches with $63M to rapidly advance a pipeline of allosteric modulator small molecules for patients with neurological disorders.

Full Article